[The body's responsiveness and the efficiency of antihomotoxic therapy for chronic opisthorchiasis: 2. Therapy].
The authors propose a new treatment policy for opisthorchiasis, which is intended for the body's self-regulation and based on the use of antihomotoxic therapy. Forty patients with the verified diagnosis of chronic opisthorchiasis were examined. Antihomotoxic therapy was found to have high clinical (85%) and parasitological (75%) effects, The application of an aggregate clinical estimate showed a positive role of episodes of development of acute inflammatory reactions, fever, and reversion of prior diseases, which favors the restoration of the body's responsiveness and the particular efficiency of the therapy performed. The results of helminthoovoscopy are interpreted in the context of clinical data. There was a significant increase in the count of HLA DR monocytes and in the level of IgA and a reduction in IgE and IL-4 with a substantial rise in the cellular production of other cytokines.
Tolokonskaia
N P
NP
Chabanov
D A
DA
D000286:Administration, Sublingual; D000328:Adult; D000818:Animals; D002675:Child, Preschool; D002908:Chronic Disease; D016207:Cytokines / Q000096:biosynthesis; D004334:Drug Administration Schedule; D006684:HLA-DR Antigens; D006801:Humans; D007273:Injections, Intramuscular; D007958:Leukocyte Count; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation; D008419:Materia Medica / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D009889:Opisthorchiasis / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
D016207:Cytokines; D006684:HLA-DR Antigens; D008419:Materia Medica